CA
SLDB icon

Clearstead Advisors’s Solid Biosciences SLDB Stock Holding History

Clearstead Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60 Buy
+6
New +$45 ﹤0.01% 3452
2025
Q3 		– Sell
-9
Closed -$44 – 3230
2025
Q2 		$44 Buy
+9
New +$32 ﹤0.01% 2680

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Clearstead Advisors's SLDB Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Solid Biosciences (SLDB) in Q2 2026: 6 shares worth $60. The stake represents ﹤0.01% of the portfolio and ranks #3452 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in SLDB as recently as Q2 2025.

Clearstead Advisors first reported a position in SLDB in Q2 2025 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Clearstead Advisors held 6 shares of Solid Biosciences worth $60 as of Q2 2026.
  • Solid Biosciences was a new Clearstead Advisors position in Q2 2026.
  • Solid Biosciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3452 holding.
  • Clearstead Advisors first reported a position in Solid Biosciences in Q2 2025 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.